1. CMU Intellectual Repository
  2. Academic Support Units
  3. Chiang Mai University Library
  4. CMUL: Journal Articles
Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/70954
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNattapong Tidwongen_US
dc.contributor.authorPreecha Montakantikulen_US
dc.contributor.authorWeerawat Manosuthien_US
dc.date.accessioned2020-10-14T08:45:29Z-
dc.date.available2020-10-14T08:45:29Z-
dc.date.issued2020-01-01en_US
dc.identifier.issn25868470en_US
dc.identifier.issn25868195en_US
dc.identifier.other2-s2.0-85085214601en_US
dc.identifier.other10.29090/psa.2020.02.020.0026en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85085214601&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/70954-
dc.description.abstract© Faculty of Pharmacy, Mahidol University (Thailand) 2020. As of March 22, 2020, a total of 292,142 confirmed coronavirus disease 2019 (COVID-19) cases have been reported globally. Although there are currently no specific antiviral agents but all coronaviruses shared similar key elements of target for currently approved antiviral or new drug development. Several agents might be considered as a possible treatment based on the efficacy in SARS and MERS.en_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titlePharmacological treatment for the novel coronavirus disease 2019 (COVID-19 infection)en_US
dc.typeJournalen_US
article.title.sourcetitlePharmaceutical Sciences Asiaen_US
article.volume47en_US
article.stream.affiliationsMahidol Universityen_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsBamrasnaradura Infectious Diseases Instituteen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.
Show simple item record


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.